Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a. For more information about its clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

AstraZeneca

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Burning Rock Dx

Burning Rock Dx (NASDAQ: BNR) is committed to providing NGS-based testing for cancer patients, biomarker detection and companion diagnostic development services to pharmaceutical partners, and NGS-based multi-cancer early detection testing.

We focus on providing tumor genomic data solutions, clinical trial solutions, integrated CDx development, and precision patient recruitment for pharmaceutical companies, thereby efficiently facilitating the entire process of anti-cancer drug development.

Daiichi Sankyo, Inc. 

With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

Janssen Asia Pacific 

At Janssen Oncology, we have a bold vision – the elimination of cancer.

This is what drives us to push the boundaries of science to help patients live cancer-free for longer than ever before.

On the back of 30 years of innovation in oncology1, our first-in-class therapies in solid tumors and hematological malignancies have extended lives and established new standards of care.

Yet we continue to pursue every avenue to suppress, destroy and ultimately eliminate cancer – seeking not just incremental, but monumental change as we concentrate on where we can make the biggest difference. It is this focus on the needs of patients and their families that has propelled us to be among the top 5 and fastest growing oncology companies globally1, with no less than ten transformational therapies approved in the last decade1.

We focus on making hope and possibility a reality. Harnessing cutting-edge research platforms for personalized medicines, we continue to pursue the most compelling science to give an increasing number of people more time to live well, live longer and live cancer-free.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.

Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Asia Pacific, a division of Johnson and Johnson International (Singapore) is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Novartis

Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more at https://www.novartis.com

Pfizer Oncology

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

Regeneron

Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions. https://www.regeneron.com/

Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

For more information, please visit www.roche.com.

Roche in Oncology

Our mission has been to turn science into breakthroughs to deliver better outcomes for everyone facing a cancer diagnosis. Today, we’re studying treatments for a wide array of cancers, with nearly 150 ongoing clinical trials and 22 breakthrough therapy designations in oncology. Our research is backed by our investment of over 13B CHF in R&D, more than any other healthcare company in the world.

We are committed to personalising cancer care for all patients and continue to focus on developing innovative medicines across various types of haematologic malignancies and solid tumours. We are leveraging multiple treatment approaches, including targeted therapies, cancer immunotherapies, cell and gene therapies, and next generation vaccines, and bringing innovation into earlier stages of disease to maximise a chance of cure.

Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi’s Specialty Care business is committed to meeting significant unmet medical needs. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer. Through rigorous drug discovery and development rooted in cutting-edge science and innovative technologies, we are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofi.com

Scanlan International

Celebrating Over 100 Years and Our Journey Continues!

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Proudly crafting Scanlan® LEGACY Needle Holders and Forceps; featuring our new revolutionary Scan- II™ handle design. Full line Scanlan® VATS instruments including D’Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps and Khan Decortication Grasper.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen

Abbvie

Boehringer Ingelheim International Gmbh

MSD

BeiGene

GSK

Thermo Fisher

NGeneBio